標(biāo)題: Titlebook: Disease Recurrence After Liver Transplantation; Natural History, Tre Paul J. Thuluvath Book 2016 Springer Science+Business Media New York 2 [打印本頁] 作者: otitis-externa 時間: 2025-3-21 20:05
書目名稱Disease Recurrence After Liver Transplantation影響因子(影響力)
書目名稱Disease Recurrence After Liver Transplantation影響因子(影響力)學(xué)科排名
書目名稱Disease Recurrence After Liver Transplantation網(wǎng)絡(luò)公開度
書目名稱Disease Recurrence After Liver Transplantation網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Disease Recurrence After Liver Transplantation被引頻次
書目名稱Disease Recurrence After Liver Transplantation被引頻次學(xué)科排名
書目名稱Disease Recurrence After Liver Transplantation年度引用
書目名稱Disease Recurrence After Liver Transplantation年度引用學(xué)科排名
書目名稱Disease Recurrence After Liver Transplantation讀者反饋
書目名稱Disease Recurrence After Liver Transplantation讀者反饋學(xué)科排名
作者: debase 時間: 2025-3-22 00:09
ent?and Survival. serves as a comprehensive reference for physicians and surgeons who take care of liver transplant recipients and a major addition to the literature detailing the current understanding of disease recurrence..978-1-4939-4137-7978-1-4939-2947-4作者: LEER 時間: 2025-3-22 01:06 作者: 糾纏 時間: 2025-3-22 07:18 作者: 完成才能戰(zhàn)勝 時間: 2025-3-22 11:09
https://doi.org/10.1007/978-3-031-08961-9isease. Recurrence of alcoholic liver disease post-transplantation is a multifaceted problem that differs in scope from recurrence of viral hepatitis, autoimmune hepatitis, and primary sclerosing cholangitis. Multidisciplinary treatment plans that begin pretransplant and continue into the post-trans作者: 使迷惑 時間: 2025-3-22 13:07
Ivica Milevski,Ekaterina Ivanovas are limited for recurrent PSC. For these important entities affecting PSC patients after liver transplantation, we review the current published data on epidemiology, diagnostic criteria, risk factors, graft and patient survival, and treatment of recurrent PSC.作者: 使迷惑 時間: 2025-3-22 18:36
https://doi.org/10.1007/978-3-319-27905-3urvival (~70 %). The UNOS data also suggested that the survival improved after the publication of Milan criteria in the United States. There is an ongoing debate whether Milan criteria could be expanded without having an adverse effect on tumor-free survival. Published studies suggest that HCC patie作者: AGATE 時間: 2025-3-22 22:11 作者: 門窗的側(cè)柱 時間: 2025-3-23 03:19 作者: 壓迫 時間: 2025-3-23 06:16
Raymond Charles Rauscher,Salim Momtazmodal therapies including neoadjuvant chemotherapy and/or radiation, and surgical exploration followed by LTX offer patient survival rates comparable to LTX done for other liver disease etiologies in a select group of patients. At this time, LTX for cholangiocarcinoma should be performed using stric作者: 擦試不掉 時間: 2025-3-23 11:14 作者: Orchiectomy 時間: 2025-3-23 14:28 作者: RODE 時間: 2025-3-23 19:12 作者: Haphazard 時間: 2025-3-23 22:22 作者: ATRIA 時間: 2025-3-24 03:28
Treatment of Recurrent Hepatitis C,e the natural history of recurrent hepatitis. Preliminary studies indicate that approximately 90 % of people with recurrent HCV could be cured with a combination of direct acting antiviral drugs with minimal side effects.作者: fertilizer 時間: 2025-3-24 08:52 作者: 顛簸下上 時間: 2025-3-24 12:01
Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation,s are limited for recurrent PSC. For these important entities affecting PSC patients after liver transplantation, we review the current published data on epidemiology, diagnostic criteria, risk factors, graft and patient survival, and treatment of recurrent PSC.作者: 千篇一律 時間: 2025-3-24 17:21 作者: 盤旋 時間: 2025-3-24 19:51
Recurrence of HCC When Transplanted Outside Milan Criteria,r LT. The main disadvantage of this set of criteria is that it is relatively restrictive. Several attempts have been made to expand these criteria to include tumors of greater number and size. The model for end-stage liver disease (MELD) prioritization system has utilized the Milan criteria since ad作者: Acupressure 時間: 2025-3-24 23:09
Role of Neoadjuvant and Adjuvant Treatment in HCC Recurrence After Liver Transplantation, the Milan criteria have been shown to be 8–15 % and higher in those patients beyond the Milan criteria. The value of adjuvant therapy using systemic cytotoxic chemotherapy after LT has been disappointing. Sorafenib has been used for treatment in recurrent HCC after LT, and the data of safety and ef作者: 入會 時間: 2025-3-25 04:28
Cholangiocarcinoma,modal therapies including neoadjuvant chemotherapy and/or radiation, and surgical exploration followed by LTX offer patient survival rates comparable to LTX done for other liver disease etiologies in a select group of patients. At this time, LTX for cholangiocarcinoma should be performed using stric作者: Gullible 時間: 2025-3-25 07:45
Recurrent Non-hepatic and De Novo Malignancies After Liver Transplantation,rson-years calculated by adding survival of each patient) are compared with epidemiological data for each cancer type. This method provides the precise incidence of cancer post-LTx compared to general population. Rates of malignancy increase in proportion to age at transplant and length of follow-up作者: 稱贊 時間: 2025-3-25 13:18 作者: commodity 時間: 2025-3-25 17:31 作者: 不適當(dāng) 時間: 2025-3-25 22:13
Ivica Milevski,Ekaterina Ivanovaotentially reverses the consequences and complications of the initial abnormalities depending on the severity of the complications, reversibility, and time interval between the diagnosis of the problem and replacement of the liver.作者: 橫條 時間: 2025-3-26 00:09 作者: 闡釋 時間: 2025-3-26 04:47 作者: Cerumen 時間: 2025-3-26 11:05
vered.As there is a high incidence of disease recurrence after liver transplantation, this volume is designed around the need for a reference text dealing exclusively with this problem. The book places special emphasis on pre- and post-transplant predictors of recurrence, severity assessment, prophy作者: forager 時間: 2025-3-26 14:10 作者: 北京人起源 時間: 2025-3-26 18:50
Ivica Milevski,Ekaterina Ivanovaion resulting in cardiovascular events—which is considered today the leading cause of death following liver transplantation in NASH recipients, surpassed only by sepsis. Patients with NASH cirrhosis should be carefully evaluated and selected for liver transplantation, and metabolic risk factors should be treated aggressively.作者: 使閉塞 時間: 2025-3-26 23:38
Nonalcoholic Fatty Liver Disease Post-Liver Transplantation,ion resulting in cardiovascular events—which is considered today the leading cause of death following liver transplantation in NASH recipients, surpassed only by sepsis. Patients with NASH cirrhosis should be carefully evaluated and selected for liver transplantation, and metabolic risk factors should be treated aggressively.作者: fatty-acids 時間: 2025-3-27 04:35
https://doi.org/10.1007/978-3-658-14428-9pear to have a major impact on graft survival. De novo diseases specific to LT recipients may also appear after LT in both adults and children. Early recognition of recurrent disease and de novo conditions will improve the survival of LT recipients.作者: 善于 時間: 2025-3-27 08:46 作者: 昏迷狀態(tài) 時間: 2025-3-27 13:04 作者: 不真 時間: 2025-3-27 13:37
Overview: Disease Recurrence After Liver Transplantation,pear to have a major impact on graft survival. De novo diseases specific to LT recipients may also appear after LT in both adults and children. Early recognition of recurrent disease and de novo conditions will improve the survival of LT recipients.作者: 燈絲 時間: 2025-3-27 21:51 作者: PAD416 時間: 2025-3-28 01:56
Recurrence of Autoimmune Hepatitis After Liver Transplantation,in the graft of those grafted for other indications. Originally termed de novo autoimmune hepatitis, some now believe this is better termed plasma cell hepatitis and is a form of rejection. Treatment is with corticosteroids or modification of immunosuppression.作者: adroit 時間: 2025-3-28 02:49 作者: ALIEN 時間: 2025-3-28 06:51 作者: 裹住 時間: 2025-3-28 13:59
HCV Recurrence: Predictors and Outcomes After Liver Transplantation,). Reinfection occurs invariably in those who are viremic at transplantation resulting in recurrent disease with uncertain outcome. Several factors, in particular, donor age, have shown to influence the natural history of HCV post-transplantation. Understanding which factors determine disease and pa作者: 車床 時間: 2025-3-28 16:52
Treatment of Recurrent Hepatitis C,is B. The predominant reason for the lower survival rate of people who have hepatitis C infection is HCV recurrence leading to cirrhosis and liver failure. In liver transplant recipients, fibrosis progresses at an accelerated rate, resulting in cirrhosis in 30 % of transplant recipients within 5 yea作者: Etching 時間: 2025-3-28 21:23
Recurrence of Autoimmune Hepatitis After Liver Transplantation,e diagnosis, the reported incidence varies but recurrence may occur in around one third of patients at a median time of around 2–3 years but may occur as late as 10 years after transplant. Treatment of recurrent disease with the addition or increase in corticosteroids is often successful, although l作者: 悶熱 時間: 2025-3-29 01:23
Alcoholic Cirrhosis, Transplantation, and Recurrence of Disease,f alcoholism and recidivism have challenged absolute approaches to define periods of pretransplant sobriety, but may further complicate recurrence of any alcohol use post-transplant. Rates of recidivism are reported at approximately 30 %, but recurrent disease leading to allograft damage is limited 作者: Ferritin 時間: 2025-3-29 04:32 作者: CHART 時間: 2025-3-29 10:41 作者: tariff 時間: 2025-3-29 12:32
Nonalcoholic Fatty Liver Disease Post-Liver Transplantation, cause of chronic liver disease and cirrhosis or liver cancer secondary to fatty liver disease may become the most common indication for liver transplantation in the Western world in the near future. Recurrence of fatty liver disease following liver transplantation is not unusual—leading at least in作者: 來自于 時間: 2025-3-29 16:55 作者: 才能 時間: 2025-3-29 19:44
Recurrence of HCC When Transplanted Outside Milan Criteria,over half a million new cases diagnosed annually. It is presently the second leading cause of cancer-related mortality in the world; the disease burden is highest in Eastern Asian and in sub-Saharan areas with endemic HBV infection. With respect to any available treatment for liver cancer, liver tra作者: CAB 時間: 2025-3-30 01:17
Role of Neoadjuvant and Adjuvant Treatment in HCC Recurrence After Liver Transplantation,directed therapy before LT has been used as a bridging therapy and as a down-staging method for patients with intermediate HCC. Transarterial chemoembolization (TACE) and radiofrequency ablation are effective treatments that can down-stage intermediate staged HCC to fulfill Milan criteria for LT. Ne作者: Ebct207 時間: 2025-3-30 06:36
Cholangiocarcinoma, with incidental tumors found at the time of transplant, due to early recurrence of tumors and mortality related to recurrent cancer. Recurrent tumors are found as adenopathy or in distant sites such as bone, lungs, or in the liver allograft. De novo cholangiocarcinoma can occur after LTX in the bil作者: dilute 時間: 2025-3-30 11:43 作者: 混合物 時間: 2025-3-30 13:09
Recurrence of Disease After Liver Transplantation in the Pediatric Population,t which is seen in adults. Chemotherapy followed by liver transplantation as primary treatment for hepatic malignancies such as hepatoblastoma and hepatocellular carcinoma yields excellent outcomes with low recurrence rates, even in the presence of locally advanced tumors. End-stage liver disease se作者: 女歌星 時間: 2025-3-30 17:52 作者: 滔滔不絕地說 時間: 2025-3-30 21:12
https://doi.org/10.1007/978-1-4939-2947-4Autoimmune hepatitis; HCV; Hepatitis B; Hepatoblastoma; Milan Criteria; NAFLD; hepatology作者: 非秘密 時間: 2025-3-31 02:59 作者: 光亮 時間: 2025-3-31 07:46 作者: indemnify 時間: 2025-3-31 12:51
Sustainable Mobility in Metropolitan Regions liver function, delay or obviate the need for liver transplantation in some patients and reduce the risk of HBV recurrence. The combination of long-term antiviral and low-dose hepatitis B immune globulin can effectively prevent HBV recurrence in >90 % of transplant recipients. Some form of HBV prop作者: 自戀 時間: 2025-3-31 16:00
Sustainable Mobility in Metropolitan Regions). Reinfection occurs invariably in those who are viremic at transplantation resulting in recurrent disease with uncertain outcome. Several factors, in particular, donor age, have shown to influence the natural history of HCV post-transplantation. Understanding which factors determine disease and pa
